Quick Connect Send a message
Health Canada’s market authorisation for our generic Semaglutide Injection makes us the first company to receive this authorisation in Canada. This milestone reflects our deep focus on complex generics and peptide‑based therapies, underpinned by integrated API and formulation development capabilities.
With launch preparations underway, we are working to enable timely access to an important treatment option for people living with diabetes in Canada.
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.
+91 4049002253